pancreatic and biliary secretion. 10 Both central (intracerebroventricular) and peripheral (intraperitoneal) injection of neurotensin acutely reduces food intake in rats, an effect mediated through Ntsr1. 11, 12 In obese as compared with normalweight humans, postprandial plasma neurotensin concentration was reduced following a liquid fatty meal 13 and increased after gastric bypass (Rouxen-Y) treatment, 14, 15 suggesting that regulation of neurotensin secretion is disturbed in human obesity. However, no study has investigated if and how neurotensin is related to measures of obesity or to obesity-associated diseases in the general population.
Neurotensin has trophic effects both on normal and neoplastic tissue and neurotensin and Ntsr1 have been suggested to be prognostic tumor biomarkers. 16, 17 Neurotensin and Ntsr1 expression is common in human malignant ductal breast cancer tumors, and in mice xenografted with a malignant human breast cancer cell line, pharmacological blockade or RNA silencing of Ntsr1 reduces tumor growth. 18, 19 In addition, genetic variation of 1 of the 3 receptors for neurotensin, ie, Ntsr3 (SORT1), is linked to development of coronary artery disease in humans, an effect mediated by elevated levels of low-density lipoprotein cholesterol (LDL-C). 20, 21 We hypothesized that variations of the neurotensin system may contribute to development of common diseases associated with elevated body mass index (BMI). Because mature neurotensin is unstable both in vitro and in vivo, we measured a stable 117-amino acid fragment from the N-terminal part of the pre-proneurotensin/ neuromedin precursor hormone, referred to as proneurotensin, which is produced in stoichiometric amounts relative to the mature neurotensin. 22 Certain tissues partially produce large peptides composed of proneurotensin connected to the peptide sequences corresponding to the mature hormones ( l a r g e n e u r o t e n s i n a n d l a r g e neuromedin). 23 These large hormones have been shown to weakly bind and activate Ntsr1
23
; however, it is unknown if proneurotensin has biological activity. In this study, we explored whether fasting concentration of proneurotensin is associated with future risk of diabetes mellitus, cardiovascular disease, and breast cancer, as well as with death.
METHODS

Study Population
The Malmö Diet and Cancer (MDC) study is a population-based, prospective epidemiologic cohort of 28 449 men (born 1923-1945) and women (born 1923-1950 ) from Malmö , Sweden, who underwent baseline examinations between 1991 and 1996.
24 From this cohort, 6103 individuals were randomly selected to participate in the MDC Cardiovascular Cohort (MDC-CC), which was designed to investigate the epidemiology of carotid artery disease between 1991 and 1994. 25 Fasting plasma samples were available for analysis of proneurotensin in 4632 participants in the MDC-CC. The 1471 excluded participants (due to lack of plasma sample) were slightly younger, but did not otherwise differ in terms of sex, smoking, diabetes, hypertension status, BMI, or plasma lipids as detailed in the eAppendix (available at http://www.jama.com).
Of the 4632 participants in whom proneurotensin was measured, those with prevalent disease prior to the baseline examination were excluded from the analyses of the main outcomes, as well as those without complete data on covariates. The baseline examination procedure has been described previously (eAppendix). [26] [27] [28] Proneurotensin was measured in stored fasting plasma specimens that were frozen to −80°C immediately at the MDC-CC baseline examination using a recent chemiluminometric sandwich immunoassay to detect a proneurotensin precursor fragment (proneurotensin 1-117) (eAppendix). 22 Following procedures (eAppendix) previously described, [26] [27] [28] [29] [30] we used Swedish national and local registers to retrieve incident cases of diabetes mellitus, cardiovascular disease (myocardial infarction and stroke), breast cancer, and all-cause and cause-specific mortality during more than 12 years of follow-up. Follow-up extended to January 1, 2009, for all end points except for new-onset diabetes, for which follow-up extended to June 30, 2006 .
All participants gave written informed consent and the study was approved by the ethical committee at Lund University, Lund, Sweden.
Statistics
We used multivariate Cox proportional hazards models to test the relationship between fasting plasma concentration of proneurotensin and each of the outcomes. Because we had primary hypotheses of association between proneurotensin and each of the outcomes, we did not adjust for multiple comparisons. In analyses of incident diabetes, we adjusted for age, sex, use of antihypertensive medication, systolic blood pressure, BMI, waist circumference, prevalent cardiovascular disease, current smoking, and fasting concentrations of glucose, highdensity lipoprotein cholesterol (HDL-C), LDL-C, triglycerides, and insulin (diabetes risk factors).
In analyses of incident cardiovascular disease, all-cause mortality and cardiovascular mortality, we adjusted for age, sex, use of antihypertensive medication, systolic blood pressure, BMI, current smoking, diabetes mellitus, and fasting concentrations of HDL-C and LDL-C (cardiovascular disease risk factors). In analyses of incident breast cancer (women only), we adjusted for age, use of antihypertensive medication, use of hormone therapy, ever use of oral contraceptives, educational level, age at menarche, number of children, menopausal status, systolic blood pressure, BMI, diabetes mellitus, current smoking, prevalent cardiovascular disease, heredity for cancer, and fasting concentrations of HDL, LDL and insulin (breast cancer risk factors). All analyses were analyzed and checked for multicollinearity between covariates but no significant multicollinearity was found in any analyses.
Fasting plasma concentration of proneurotensin was skewed to the right and therefore transformed with the natural logarithm and thereafter normalized, and hazard ratios (HRs) were expressed per 1 (SD) increment of logtransformed proneurotensin in the Cox proportional hazards models. In addition, proneurotensin was divided into quartiles. Quartile 1 (lowest values of proneurotensin) was defined as the reference standard and quartiles 2 to 4 were compared with the reference quartile in the Cox proportional hazards models.
All analyses were performed with Stata statistical software version 11. A 2-sided P value of less than .05 was considered statistically significant.
RESULTS
Cross-sectional Relationship Between Cardiometabolic Risk Factors and Proneurotensin
The baseline characteristics are shown in The relationship between proneurotensin and cardiometabolic risk factors was weak, with the strongest correlation being that with fasting insulin concentration in both sexes (eTable 3). In a linear regression model with backward elimination and a retention P Ͻ .10, significant independent determinants of proneurotensin were smoking and fasting concentrations of insulin, glucose, and HDL (all positive) in women, and smoking and fasting concentrations of insulin and HDL (positively related) and age and LDL (negatively related) in men (TABLE 2).
Proneurotensin and Risk of Diabetes Mellitus
Among 3704 participants free from diabetes mellitus at baseline (1484 men and 2220 women), 142 (68 men and 74 women) developed new-onset diabetes mellitus during a median (IQR) follow-up time of 13.2 years (12.6-13.7) with an event rate of 30.2 per 10 000 person-years. Each SD increase of baseline proneurotensin was associated with a multivariateadjusted HR of 1.28 (95% CI, 1.09-1.50; P = .003) for the risk of newonset diabetes in the total study population, whereas the HR was 1.41 (95% CI, 1.12-1.77; P = .003) in women, and not significantly elevated in men (HR, 1.21; 95% CI, 0.96-1.53; P = .10). There was no significant interaction between sex and proneurotensin regarding the association with new-onset diabetes (P = .37). Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol. a P values are for continuous analyses of association between proneurotensin and outcomes. b Analyses of incident cardiovascular disease, all-cause mortality, and cardiovascular mortality were adjusted for age, sex, use of antihypertensive medication, systolic blood pressure, BMI, current smoking, diabetes mellitus, and fasting HDL-C and LDL-C. c Because participants included and the respective proneurotensin values (fasting plasma concentration) are the same for cardiovascular disease, all-cause mortality, and cardiovascular mortality, proneurotensin values are only shown for cardiovascular disease and breast cancer. d HRs (95% CIs) are expressed per 1-SD increment of log-transformed proneurotensin (in analyses of all participants, all men, and all women). e Analysis of incident breast cancer in women was adjusted for age, use of antihypertensive medication, hormone therapy, ever use of oral contraceptives, educational level, age at menarche, number of children, menopausal status, systolic blood pressure, BMI, diabetes mellitus, current smoking, prevalent cardiovascular disease, heredity for cancer, and fasting concentrations of HDL-C, LDL-C, and insulin. of 1.47 (1.08-2.00; P = .01) for incident diabetes. 3) . There was a significant interaction between proneurotensin and female sex on incidence of cardiovascular disease (P Ͻ .001) and sexstratified analyses revealed that each SD increase of baseline proneurotensin was associated with a hazard ratio of 1.33 (95% CI, 1.17-1.51) and top vs bottom quartile of proneurotensin with a hazard ratio of 1.65 (95% CI, 1.13-2.41) for risk of cardiovascular disease in women, whereas there was no significant relationship among men (Table 3) . Each SD increment of proneurotensin was associated with a hazard ratio of 1.08 (95% CI, 1.00-1.17) for risk of all-cause mortality in the total population and a hazard ratio of 1.13 (95% CI, 1.01-1.27) for risk of all-cause mortality among women, with no increased risk related to proneurotensin in men ( Table 3 ). The excess risk of death associated with proneurotensin in women appeared to be mainly accounted for by cardiovascular deaths with a hazard ratio of 1.50 (95% CI, 1.20-1.87) per SD increment of proneurotensin and 2.18 (95% CI, 1.13-4.20) in women belonging to the top as compared with the bottom quartile of proneurotensin (Table 3) . There was no significant interaction between sex and proneurotensin regarding the association with all-cause (P = .26) and cardiovascular mortality (P=.08).
Proneurotensin and Breast Cancer in Women
During a median follow-up time of 15.7 years (IQR, 15.1-16.2) of 1929 women without cancer prior to the baseline examination, there were 123 incident cases of breast cancer with an event rate of 43.2 per 10 000 personyears. The cumulative incidence of breast cancer in quartiles of baseline fasting plasma concentration of proneurotensin is depicted in the FIGURE. After adjustment for breast cancer risk factors, each SD increase of proneurotensin was associated with an HR of 1.44 (95% CI, 1.21-1.71) for the risk of future breast cancer, and the top vs bottom quartiles of proneurotensin were associated with an HR of 2.44 (95% CI, 1.44-4.15) for risk of breast cancer (Table 3 ). In a model including a more limited set of breast cancer risk factors (age, use of hormone therapy, ever use of oral contraceptives, educational level, age at menarche, number of children, menopausal status, BMI, current smoking, and heredity for cancer), each SD increase of proneurotensin was associated with an HR of 1.42 (95% CI, 1.19-1.67; PϽ .001) for risk of breast cancer.
COMMENT
To our knowledge, this is the first epidemiological study on fasting concentration of proneurotensin, a stable Nterminal fragment of the precursor of the satiety hormone neurotensin, in relation to risk of future disease. We show that proneurotensin is associated with the development of diabetes mellitus, cardiovascular disease, total mortality, cardiovascular mortality, and breast cancer in women during long-term follow-up.
The relationship between proneurotensin and morbidity and mortality was only significant in women. It has been repeatedly shown that estradiol up-regulates expression of neurotensin. 18, 31, 32 Thus, it can be speculated that the higher proneurotensin observed in women than in men, and the fact that the association between proneurotensin and adverse outcomes was only significant in women, is partially explained by higher lifetime exposure to estrogen in women than in men. It should be noted that our study population included more women than men and that the interaction between proneurotensin and sex was only significant for the endpoint of incident cardiovascular dis- Kaplan-Meier plot shows 1 minus cumulative breast cancer event-free survival during follow-up in quartiles: first (lowest values) to fourth quartile of the baseline fasting plasma concentration of proneurotensin. Median (range) concentrations of the quartiles 1 to 4 are shown in Table 3 . The numbers at risk are shown at 2-year intervals.
ease. Thus, we cannot exclude that there may exist an association between proneurotensin and adverse outcomes also in men.
The elevation of proneurotensin several years before onset of disease indicates that proneurotensin is a marker of underlying disease susceptibility rather than being an expression of subclinical disease. As an observational study, our results do not prove any causation between proneurotensin and cardiometabolic disease and breast cancer. Two limitations of our study to consider when interpreting the results are that we did not correct for multiple comparisons and that we lack a replication cohort. Our results warrant replication in other prospective population-based studies and should encourage further research aimed at testing whether targeting the neurotensin system may have advantageous effects in preventing these common diseases in animal models and ultimately in humans.
As a satiety hormone, one may intuitively expect that high levels of proneurotensin would be related to less overeating and thus less obesity, diabetes, and cardiovascular disease. In contrast, high proneurotensin was persistently associated with increased risk of morbidity and mortality in women. The cause of this relationship is unclear. The key metabolic actions of neurotensin include digestion and metabolism of fat. 8, 10 One can speculate that high plasma proneurotensin in the fasting state may be a result of compensatory increase in secretion of neurotensin due to resistance to the actions of neurotensin at the level of either its receptors or downstream of them, ie, neurotensin resistance.
Whatever the cause of high proneurotensin, experimental studies demonstrating increased expression of neurotensin and Nstr1 in breast tumors and reduced tumor growth after pharmacological blockade or RNA silencing of Ntsr1 18, 19 lend support to a direct, mechanistic relationship between high-fasting proneurotensin and breast cancer development. Whereas the links between neurotensin and breast cancer are likely to be mediated through the Ntsr1, the major candidate receptor linking neurotensin to cardiovascular disease and diabetes is the Ntsr3 (SORT1), a protein that sorts various luminal proteins from the trans-Golgi. We and others identified genetic variation of the Ntsr3 as one of the strongest common susceptibility genes for coronary artery disease in the genome, an effect mediated through elevated levels of LDL-C. 20, 21 In addition, Ntsr3 has been suggested to be an insulinsensitive regulator of the key glucose transporter in muscle and adipose tiss u e , i e , g l u c o s e t r a n s p o r t e r 4 (GLUT4), 33 suggesting a role of the neurotensin system not only in metabolism of LDL-C and coronary artery disease but also in insulin resistance and diabetes development. In fact, fasting insulin concentration was one of the strongest correlates of proneurotensin.
Thus, it could be expected that insulin-resistant women, such as those with polycystic ovary syndrome, would drive the association with diabetes and cardiovascular disease in women. However, we had no data on polycystic ovary syndrome, however, the relationship between proneurotensin and cardiometabolic diseases was independent from both fasting insulin concentration and LDL-C. Thus, the mechanisms behind the relationship between high proneurotensin and cardiometabolic diseases remain to be identified.
In conclusion, fasting proneurotensin was significantly associated with development of diabetes, cardiovascular disease, breast cancer, and with total and cardiovascular mortality. The relationships between proneurotensin and all end points were significant in women but not in men; however, because there was only significant interaction between sex and proneurotensin for the outcome of incident cardiovascular disease, it remains to be shown whether the association between proneurotensin and adverse outcome is specific for women.
